SEC Info - Nymox Pharmaceutical Corp

SEC Info℠

Home

Help

Please Sign In

Nymox Pharmaceutical Corp – ‘6-K’ for 9/30/19

On: Wednesday, 11/13/19, at 3:36pm ET · For: 9/30/19 · Accession #: 1640334-19-2273 · File #: 1-12033

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/13/19  Nymox Pharmaceutical Corp         6-K         9/30/19   40:1.5M                                   Pubco Reporting … Inc/FA

Report by a Foreign Issuer — Form 6-K — Rule 13a-16 / 15d-16
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report by a Foreign Issuer                          HTML     18K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    247K 
 4: EX-99.2     Ex-99.3                                             HTML     21K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     21K 
27: R1          Document and Entity Information                     HTML     27K 
36: R2          Consolidated Statements of Operations (Unaudited)   HTML     51K 
32: R3          Consolidated Statements of Financial Position       HTML     74K 
14: R4          Consolidated Statements of Financial Position       HTML     15K 
                (Parenthetical)                                                  
26: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML     70K 
35: R6          Consolidated Statements of Changes in Equity        HTML     44K 
                (Unaudited)                                                      
30: R7          Basis of preparation                                HTML     19K 
15: R8          Liquidity, Going Concern and Management?s Response  HTML     16K 
25: R9          Share capital                                       HTML     49K 
17: R10         Earnings per share                                  HTML     25K 
21: R11         Operating lease and other commitment                HTML     24K 
39: R12         Related Party Transactions                          HTML     28K 
28: R13         Subsequent events                                   HTML     15K 
18: R14         Share capital (Tables)                              HTML     46K 
22: R15         Earnings per share (Tables)                         HTML     24K 
40: R16         Operating lease and other commitment (Tables)       HTML     23K 
29: R17         Related Party Transactions (Tables)                 HTML     24K 
19: R18         Share capital (Details)                             HTML     36K 
20: R19         Share capital (Details 1)                           HTML     22K 
37: R20         Share capital (Details 2)                           HTML     19K 
33: R21         Share capital (Details Narrative)                   HTML     36K 
12: R22         Earnings per share (Details)                        HTML     21K 
23: R23         Operation lease and other commitment (Details)      HTML     18K 
38: R24         Operation lease and other commitment (Details 1)    HTML     22K 
34: R25         Operation lease and other commitment (Details       HTML     27K 
                Narrative)                                                       
13: R26         Related Party Transactions (Details)                HTML     24K 
24: R27         Related Party Transactions (Details Narrative)      HTML     19K 
31: XML         IDEA XML File -- Filing Summary                      XML     64K 
16: EXCEL       IDEA Workbook of Financial Reports                  XLSX     30K 
 5: EX-101.INS  XBRL Instance -- nymx-20190930                       XML    427K 
 7: EX-101.CAL  XBRL Calculations -- nymx-20190930_cal               XML     72K 
 8: EX-101.DEF  XBRL Definitions -- nymx-20190930_def                XML    136K 
 9: EX-101.LAB  XBRL Labels -- nymx-20190930_lab                     XML    360K 
10: EX-101.PRE  XBRL Presentations -- nymx-20190930_pre              XML    266K 
 6: EX-101.SCH  XBRL Schema -- nymx-20190930                         XSD    143K 
11: ZIP         XBRL Zipped Folder -- 0001640334-19-002273-xbrl      Zip     44K

‘6-K’ — Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the period ended September 30, 2019

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ¨

Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Exhibits

99.1		Quarterly Report for the Quarter ended September 30, 2019
99.2		CEO Certifications
99.3		CFO Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NYMOX PHARMACEUTICAL CORPORATION
	(Registrant)

	By:	/s/ *Paul Averback, MD*
		Paul Averback, MD
		President and Chief Executive Officer

Date: November 13, 2019

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed on:	11/13/19	None on these Dates
For Period end:	9/30/19
		List all Filings

↑Top

Filing Submission 0001640334-19-002273 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)